Results 181 to 190 of about 27,780 (214)
Therapeutic options for carbapenem-resistant Enterobacteriaceae infections [PDF]
Virulence, 2017 In recent years, carbapenem resistance among Enterobacteriaceae has dramatically increased and represents an important threat to global health. The optimal therapeutic management of carbapenem-resistant Enterobacteriaceae (CRE) infections has not been established, because to date, no clinical trials have been performed with this objective.
Enrico Trecarichi, Mario Tumbarello
exaly +5 more sources
The rapid spread of carbapenem-resistant Enterobacteriaceae [PDF]
Drug Resistance Updates, 2016 Carbapenems, our one-time silver bullet for multidrug resistant bacterial infections, are now threatened by widespread dissemination of carbapenem-resistant Enterobacteriaceae (CRE). Successful expansion of Enterobacteriaceae clonal groups and frequent horizontal gene transfer of carbapenemase expressing plasmids are causing increasing carbapenem ...
Gautam Dantas
exaly +3 more sources
Carbapenem‐resistant Enterobacteriaceae: biology, epidemiology, and management [PDF]
Annals of the New York Academy of Sciences, 2014 Introduced in the 1980s, carbapenem antibiotics have served as the last line of defense against multidrug‐resistant Gram‐negative organisms. Over the last decade, carbapenem‐resistant Enterobacteriaceae (CRE) have emerged as a significant public health threat.
Amos Adler
exaly +4 more sources
Carbapenem-resistant Enterobacteriaceae in the community: a scoping review [PDF]
International Journal of Antimicrobial Agents, 2017 Carbapenem antibiotics are used as a last resort to treat serious Gram-negative bacteria (GNB) infections; however, carbapenemase-producing strains of GNB have emerged as a major source of resistance. Owing to the highly transmissible nature of plasmid-borne carbapenemases, numerous reports have warned about the likely spread into the community from ...
, Barun Mathema
exaly +3 more sources
Antecedent Carbapenem Exposure as a Risk Factor for Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae and Carbapenemase-Producing Enterobacteriaceae [PDF]
Antimicrobial Agents and Chemotherapy, 2019 Carbapenem-resistant Enterobacteriaceae (CRE) can be mechanistically classified into carbapenemase-producing Enterobacteriaceae (CPE) and non-carbapenemase-producing carbapenem nonsusceptible Enterobacteriaceae (NCPCRE).
Raymond Tzer Pin Lin +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Options for treating carbapenem-resistant Enterobacteriaceae
Current Opinion in Infectious Diseases, 2014To address the therapeutic management of carbapenem-resistant Enterobacteriaceae on the basis of literature of the last 12 months.Retrospective and prospective (nonrandomized noncontrolled) studies provide data regarding the management of infections due to carbapenem-resistant Enterobacteriaceae.
Petros I, Rafailidis, Matthew E, Falagas
openaire +2 more sources
Resistance Mechanism of Carbapenem-Resistant Enterobacteriaceae to Quinolones
Clinical Laboratory, 2021To investigate the epidemics of plasmid-mediated quinolone resistance (PMQR) gene in carbapenem-resistant Enterobacteriaceae (CRE) and the resistance mechanism.We collected CRE bacteria isolated clinically between December 2017 and December 2018 for identification and drug sensitivity testing using a VITEK2 Compact Analyzer.
Ming, Wei, Na, Tu, Kai, Yang
openaire +2 more sources
The Emerging Threat From Carbapenem‐Resistant Enterobacteriaceae
Nursing for Women's Health, 2013The emergence of carbapenem-resistant enterobacteriaceae (CRE) in the United States represents a serious danger to people who are hospitalized and is associated with case mortality rates as high as 50 percent. CRE infections have limited treatment options and the potential to spread widely if prevention and transmission measures are not employed ...
Jessica, Landry, Helen, Hurst
openaire +2 more sources